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OBJECTIVES: Our objective was to analyze, in a population treated for hepatitis C infection at a tertiary care
treatment unit, the prevalence of comorbidities and extrahepatic manifestations, the range and degree of the
clinical complexity and the associations between advanced liver disease and clinical variables.
METHODS: Medical records from chronically infected hepatitis C patients seen at a dedicated treatment facility
for complex cases in the Infectious Diseases Division of Hospital das Clı´nicas in Brazil were analyzed. Clinical
complexity was defined as the presence of one or more of the following conditions: advanced liver disease
(Metavir score F3 or F4 and/or clinical manifestations or ultrasound/endoscopy findings consistent with cirrhosis)
or hepatocellular carcinoma and/or 3 or more extrahepatic manifestations and/or comorbidities concomitantly.
RESULTS: Among the 1574 patients analyzed, only 41% met the definition of being clinically complex. Cirrhosis
or hepatocarcinoma was identified in 22.2% and 1.8% of patients, respectively. According to multiple logistic
regression analysis, male sex (p=0.007), age440 years (po0.001) and the presence of metabolic syndrome
(p=0.008) were independently associated with advanced liver disease.
CONCLUSION: The majority of patients did not meet the criteria for admittance to this specialized tertiary service,
reinforcing the need to reevaluate public health policies. Enhanced utilization of existing basic and intermediate
complexity units for the management of less complex hepatitis C cases could improve care and lower costs.
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’ INTRODUCTION
Designing services with the capacity and expertise to
optimally allocate resources to meet the needs of hepatitis
C-infected populations requires a detailed understanding of
their characteristics and healthcare needs. In 2016, the World
Health Organization (WHO) adopted viral hepatitis elimina-
tion targets, aiming for a 90% reduction in new infections and a
65% reduction in mortality within the next 14 years (1). Brazil,
with an estimated 670,000 hepatitis C-infected individuals (2),
is one of nine countries currently on track to achieve hepatitis
C elimination by 2030 (3). In 2015, the Ministry of Health
concluded price negotiations with pharmaceutical companies
and gained access to affordable direct-action antivirals (4).
As of 2018, the Ministry of Health is committed to providing
free treatment for hepatitis C to all those infected (5).
Information derived from a reference center at a tertiary
care hospital can serve as a guide to identify specific defi-
ciencies, revise strategies to better meet the needs of infected
individuals and more effectively pinpoint areas for improve-
ments in public health interventions. The aims of this study
are to describe, in a large patient population treated at a
hepatitis C tertiary medical care unit in Brazil, (1) their
demographic and clinical characteristics, (2) prevalence of
comorbidities or extrahepatic manifestations, (3) the range
and degree of clinical complexity in this population, and (4)
the associations between advanced liver disease and clinical
variables. Based on this information, new recommendations
for improved clinical public health services are described.
’ MATERIAL AND METHODS
Patient population
In this retrospective study, the patients analyzed were
those registered at the Hepatitis C Outpatient Clinic in theDOI: 10.6061/clinics/2019/e1286
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Infectious Diseases Division of Hospital das Clinicas, a ter-
tiary care hospital in Sao Paulo, Brazil. This is an ambulatory
reference center specifically for patients with complex com-
plications of hepatitis C viral infections.
Hepatitis C-associated comorbidities were defined as any
cardiovascular, renal, neurological, psychiatric, dermatologi-
cal, rheumatologic or endocrinological condition associated
with this infection that required clinical or pharmacological
intervention from the attending physician. Additional com-
orbidities included conditions (gastrointestinal, pulmonary,
infectious, musculoskeletal, otorhinolaryngological, urologic
and alcohol consumption) not traditionally associated with
HCV that could have a negative impact on the response to
hepatitis C treatment or even postpone or contraindicate
intervention.
Clinical complexity was thus defined as the presence of
advanced liver disease (Metavir score F3/F4 and/or clinical
manifestations or ultrasound/endoscopy findings consistent
with cirrhosis) or hepatocarcinoma and/or 3 or more com-
orbidities or extrahepatic manifestations, including cryoglo-
bulinemia, vasculitis and other autoimmune phenomena,
lymphoproliferative disorders, systemic scleroderma, por-
phyria cutanea tarda, rheumatoid-like arthritis, lichen planus
or metabolic syndrome. Metabolic syndrome was defined as
proposed by the National Cholesterol Education Program
(NCEP) Adult Treatment Panel III (ATP III) (6), that is as the
presence of any three of the following five traits: (1) abdominal
obesity, defined as a waist circumference X102 cm (40 in) in
men and X88 cm (35 in) in women; (2) serum triglycerides
X150 mg/dL (1.7 mmol/L) or drug treatment for elevated
triglycerides; (3) serum high-density lipoprotein (HDL)
cholesterolo40 mg/dL (1 mmol/L) in men ando50 mg/dL
(1.3 mmol/L) in women or drug treatment for low HDL
cholesterol; (4) blood pressureX130/85 mmHg or drug treat-
ment for elevated blood pressure; or (5) fasting glucose
X100 mg/dL (5.6 mmol/L) or drug treatment for elevated
blood glucose.
The included patients were hepatitis C-infected patients
treated from January 2014 to December 2016, age over
18 years and viremic at enrolment. The excluded patients were
those who were negative for hepatitis C RNA (spontaneous
virus clearance) and those coinfected with HIV. Outpatient
care of HIV-infected patients occurred at another outpatient
unit, a specific ambulatory setting specifically for HIV-infected
patients and their sexual partners.
Data collection
Clinical and laboratory data were extracted from a data-
base routinely prepared and maintained for each patient.
The variables analyzed included age, sex, HIV status, hepa-
titis A and B or HTLV coinfection, hepatitis C virus genotype,
stage of liver fibrosis, and the presence of extrahepatic
manifestations and comorbidities. All patients had under-
gone a percutaneous liver biopsy, except those with clinical
manifestations or ultrasound/endoscopy findings consistent
with cirrhosis. On histopathological analysis, structural liver
injury was assessed and graded according to the Metavir
classification system (7). Extrahepatic manifestations of hepa-
titis C infection were diagnosed by standard protocols in the
appropriate clinical laboratory.
This study was approved by the Ethics Committee for
the Analysis of Research Projects (Comissão de Ética para
Análise de Projetos de Pesquisa–CAPPesq) of the Clinics
Hospital of the Medical School of the University of São Paulo
(Hospital das Clínicas da Faculdade de Medicina da Uni-
versidade de São Paulo – HC-FMUSP) under protocol no.
CAAE: 37392414.5.0000.0068, and all subjects provided infor-
med written consent.
Statistical analysis
We initially conducted an analysis of the frequency
distribution for each selected variable. Pearson’s chi-square
test was used to compare proportions of demographic,
virological, and clinical variables among patients character-
ized as complex or not complex and among individuals with
or without advanced liver disease. Continuous parameters
were compared between groups using Student’s t-test. Odds
ratios (ORs) were calculated as association measures, with
their respective 95% confidence intervals (95% CI). Two-
tailed p-values were calculated and considered statistically
significant ifo0.05. Variables with p values less than 0.20 on
bivariate analysis were selected for multivariate analysis.
Multiple logistic regression analysis was performed to
examine the association of variables with advanced liver
disease. Statistical analyses were performed using Stata
software version 13.0 (Stata Corp., College Station, TX, USA).
’ RESULTS
A total of 2,194 patients were identified in the database,
and 1574 of them were included in the final study. The
remaining 620 patients were excluded due to testing negative
for hepatitis C RNA (n=112), having HIV coinfection (n=452)
or lacking complete clinical data (n=56).
Table 1 summarizes the demographic and clinical char-
acteristics of the study population. Their mean age (standard
deviation) was 54.8 (12.3) years, and a small majority were
female (52.6%). HCV genotype 1 was most prevalent (75.4%),
followed by genotypes 3 (19.8%), 2 (3.9%), 4 (0.4%) and
5 (0.4%). All patients underwent a liver fibrosis evaluation:
12.6% had severe fibrosis (F3), 25.2% had moderate fibrosis
(F2), 33.7% had mild fibrosis (F1) and 6.4% had no evidence
of fibrosis. In addition, 22.2% had cirrhosis. Hepatocarci-
noma was diagnosed in 1.8% of the patients. The majority of
patients (62.3%) had at least one HCV-associated comorbid-
ity, while 41.2% had another comorbidity not typically
regarded as being HCV-associated.
Among our study population, only 646 (41%) met the
definition of being clinically complex. The associations between
clinical complexity and demographic and clinical characteristics
are shown in Table 2. The only variable associated with clinical
complexity was age above 40 years (po0.001).
Table 3 details the associations between advanced liver
disease and other characteristics. According to bivariate
analysis, advanced liver disease was independently asso-
ciated with male sex (p=0.012), age over 40 years (po0.001),
HCV-associated comorbidities (p=0.004), other comorbidities
(p=0.025) and the presence of metabolic syndrome (p=0.001).
According to multiple logistic regression analysis, male sex
(p=0.007), age 440 (po0.001) and the presence of metabolic
syndrome (p=0.008) remained independently associated with
advanced liver disease (Table 4).
’ DISCUSSION
The present study describes the demographic and clinical
characteristics of patients treated in a hepatitis C tertiary
2
Hepatits C in a specialized facility
de Matos MLM et al.
CLINICS 2019;74:e1286
medical care unit in Brazil and the associations between
advanced disease and clinical variables. We observed that
approximately one-third of subjects had advanced liver
disease, and 41% were clinically complex. Our observation
that 34.8% of patients had advanced liver disease parallels a
prior national investigation reporting that 28.8% of chronic
hepatitis C cases in Brazil present with advanced forms of
liver disease (2).
In our study, the level of complexity of the patients
analyzed took into consideration the presence of comorbid-
ities associated with hepatitis C virus and/or the presence of
advanced liver disease and its complications. Following the
convention of Feinstein (8), the term comorbidity refers to
any distinct clinical entity that has existed or that may occur
during the course of hepatitis C disease. As such, these are
not limited to those classically associated with this viral
infection or its treatment. It is important to mention, how-
ever, that the presence of comorbidities may not necessarily
significantly impact hepatitis C clinical management. This is
also true with respect to hepatitis C-associated extrahepatic
manifestations. Numerous extrahepatic manifestations have
been reported (9,10) that vary in severity, from clinical
situations often unobserved to highly disabling conditions.
However, to quantify the clinical situations of greater com-
plexity, we included only comorbidities that resulted in a
clinical or pharmacological intervention.
All extrahepatic manifestations were considered in the
analysis, as detailed in the inclusion criteria. In addition, we
took into account the presence of 3 or more comorbidities
or extrahepatic manifestations to define clinical complexity.
According to these criteria, only 41% of the population
analyzed had clinical comorbidities or had advanced liver
disease that justified their stay in a high-complexity hospital
unit for the care of patients with hepatitis C.
The association between advanced liver disease and
clinical variables was evaluated. According to multivariate
analysis, advanced liver disease was independently asso-
ciated with male sex, age over 40 years and the presence of
metabolic syndrome. The association of age over 40 years
with advanced liver disease has been extensively described
previously and is confirmed by our data (6,11-13). Patients’
age at the time of hepatitis C diagnosis has been shown to
be a risk factor for the progression of liver fibrosis, liver
cirrhosis, and hepatocellular carcinoma (11-13). Additionally,
the association between hepatitis C and metabolic syndrome
has been evaluated previously. HCV is thought to induce
metabolic alterations resulting in hypolipidemia, hepatic
steatosis, insulin resistance (IR), metabolic syndrome, and
diabetes. These effects may lead to clinically relevant con-
sequences affecting both liver disease progression and
response to antiviral therapy (14-16).
It is important to mention the limitations of this study.
The investigation was cross-sectional and retrospective.
Table 1 - Demographics and clinical characteristics of the study
population.
Characteristic Value
Female sex 52.6%
Mean age (SD) 54.8 (12.3) years
Age 440 years 82.0%
HCV genotype
1 75.4%
2 3.9%
3 19.8%
4 0.4%
5 0.45
Liver fibrosis
None (METAVIR F0) 6.4%
Mild (METAVIR F1) 33.7%
Moderate (METAVIR F2) 25.2%
Severe (METAVIR F3) 12.6%
Cirrhosis 22.2%
Extrahepatic manifestationsa 8.3%
Hepatocarcinoma 1.8%
HCV-associated comorbidityb 62.3%
Non-HCV-associated comorbidityc 41.2%
A total of 1,574 HCV-infected individuals were evaluated.
aExtrahepatic manifestations include the presence of cryoglobulinemia,
vasculitis and other autoimmune phenomena, lymphoproliferative
disorders, systemic scleroderma, porphyria cutanea tarda, rheumatoid-like
arthritis and lichen planus.
bHCV-associated comorbidity includes any cardiovascular, renal,
neurological, psychiatric, dermatological, rheumatologic,
endocrinological condition known to be associated with this infection
that required clinical or pharmacological intervention from the attending
physician.
cNon-HCV-associated comorbidity includes any clinical condition
(gastrointestinal, pulmonary, infectious, musculoskeletal,
otorhinolaryngological and urologic) not traditionally associated with
HCV that could have a negative impact on the response to hepatitis C
treatment or even postpone or contraindicate intervention.
Table 2 - Demographic and clinical characteristics of patients according to the presence or absence of clinical complexity.
Complexity
No Yes
Characteristic N=928 N=646 OR (IC 95%) p-value
Male sex 45.8% 49.7% 1.16 (0.96-1.43) 0.128
Female sex 54.2% 50.3% NS
Age p40 years 23.0% 11.0% NS
440 years 77.0% 89.0% 2.43 (1.08-3.22) o0.001
Genotype
1 77.5% 72.4% 0.131
2 3.8% 4.0%
3 17.9% 22.6%
4+5 0.9% 0.9%
Mean age, years (SD) 52.1 (12.2) 58.8 (11.3) o0.001
Clinical complexity is defined as the presence of one or more of the following conditions: advanced liver disease (Metavir score F3 or F4 and/or clinical
manifestations or ultrasound/endoscopy findings consistent with cirrhosis) or its consequences (hepatocellular carcinoma and/or portal hypertension)
and/or 3 or more extrahepatic manifestations and/or comorbidities concomitantly.
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Variables were obtained from a database used for patient
follow-up and, therefore, may not have been complete. In
addition, our study presents the findings of a single tertiary
center and may possibly not be representative of other
tertiary centers in Brazil or elsewhere.
Our study contained the largest cohort of patients with
chronic hepatitis C analyzed in a tertiary center in Brazil, and
the findings are consistent with and reinforce conclusions
from prior studies. The analysis reveals that the majority of
patients did not meet the criteria for admittance to this
highly complex and specialized tertiary service. Many of
these individuals could have been satisfactorily followed in
other lower complexity health units. Thus, our data rein-
forces a continued need to establish more appropriate resource
allocation and public health policies to more effectively
manage individuals with hepatitis C infection. Health services
in Brazil, as in other low- and middle-income countries, have a
limited capacity to provide specialized care for all deserving
conditions.
There are many competing priorities in health care, and all
require adequate resources and attention. The utilization of
health care providers at basic and intermediate complexity
units for the diagnosis and management of hepatitis C-
infected patients who are presently managed in more highly
specific services could result in the improved utilization of
existing resources at a lower cost. By working in collabora-
tion, these different levels of services could more effectively
advance the goals of increasing the availability of treatment
and potential for the cure of hepatitis C-infected patients. We
believe that the distribution and tasks attributed to each level
of care should also be adjusted according to regional demand
and availability. The absence of a structured cascade of
care may lead to a delay in the achievement of the targets
set by the Brazilian Ministry of Health for the elimination
of hepatitis C.
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